AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23536105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR plus intensive smoking cessation counseling
Number of subjects: 294
Study 23536105 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus intensive smoking cessation counseling
Number of subjects: 294
Study 21285475 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (3 sessions of 60 min/week for 8 weeks)
Number of subjects: 26
Study 21285475 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 19595247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (P(ET))
Number of subjects: 200
Study 19595247 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (target effect site concentration)
Number of subjects: 200
Study 16549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1 plus aprinocarsen 2 mg/kg/d as continuous infusion for 14 days
Number of subjects: 670
Study 16549837 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1
Number of subjects: 670
Study 16549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arms (gemcitabine and cisplatin with aprinocarsen)
Number of subjects: 670
Study 12735916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lining with Revolution
Number of subjects: 40
Study 12735916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lining with Tetric Flow
Number of subjects: 40
Study 12735916 — intervention group
Group type: COMPARATOR
Intervention: Restoration in bulk after cavity lining with flowable composites
Number of subjects: 40
Study 12735916 — intervention group
Group type: COMPARATOR
Intervention: Restoration in two oblique layers of high-viscosity composites
Number of subjects: 40
Study 10686267 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with a 'figure eight' coil held in various positions over the left primary motor cortex.
Number of subjects: 9
Study 10686267 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp sensation assessment with the coil in various positions over the prefrontal area.
Number of subjects: 9
Study 9266531 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 administered as a meal (30 mg/person)
Number of subjects: 0
Study 9266531 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 administered as capsules (30 mg/person)
Number of subjects: 0
Study 9266531 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme Q10 (both forms of administration)
Number of subjects: 0
Study 8141183 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 dialyzer
Number of subjects: 10
Study 8141183 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane or polysulfone dialyzers
Number of subjects: 10
Study 3440392 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 4524
Study 3440392 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 4524
Study 29708775 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing exergames (Xbox 360, 30 minutes once a week for 2 weeks)
Number of subjects: 337
Study 29708775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exergame participation)
Number of subjects: 337
Study 27570178 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP programme (intervention group)
Number of subjects: 2834
Study 27570178 — intervention group
Group type: COMPARATOR
Intervention: Standard health education curriculum (control group)
Number of subjects: 2834
Study 25254614 — intervention group
Group type: EXPERIMENTAL
Intervention: In-school intervention based on compassion, self-efficacy, emotional well-being, peer and parental support, delivered in 10 sessions.
Number of subjects: 1200
Study 25254614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1200
Study 22158731 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46)
Number of subjects: 676
Study 22158731 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg phentermine/92 mg controlled-release topiramate (15/92)
Number of subjects: 676
Study 22158731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study 20308618 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1572
Study 20308618 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study 20308618 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI) among patients at referral hospitals
Number of subjects: 1572
Study 20308618 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis among patients at referral hospitals
Number of subjects: 1572
Study 18512557 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg amikacin administered at 3-4 postburn hours (A group)
Number of subjects: 20
Study 18512557 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg amikacin administered at 10 postburn hours (B group)
Number of subjects: 20
Study 18512557 — intervention group
Group type: COMPARATOR
Intervention: 400 mg amikacin administered at 20 postburn hours (C group)
Number of subjects: 20
Study 18512557 — intervention group
Group type: COMPARATOR
Intervention: 400 mg amikacin administered at 30 postburn hours (D group)
Number of subjects: 20
Study 21190790 — intervention group
Group type: EXPERIMENTAL
Intervention: BEV+IFN
Number of subjects: 628
Study 21190790 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 628
Study 21190790 — intervention group
Group type: COMPARATOR
Intervention: Motzer criteria
Number of subjects: 628
Study 21190790 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of the novel model and Motzer criteria
Number of subjects: 628
Study 16214627 — intervention group
Group type: EXPERIMENTAL
Intervention: Round incisors (evaluated by restorative dentists)
Number of subjects: 335
Study 16214627 — intervention group
Group type: EXPERIMENTAL
Intervention: Round and square‐round incisors (evaluated by orthodontists)
Number of subjects: 335
Study 16214627 — intervention group
Group type: EXPERIMENTAL
Intervention: Square‐round incisors (evaluated by all groups)
Number of subjects: 335
Study 16214627 — intervention group
Group type: EXPERIMENTAL
Intervention: Female images rated by male judges
Number of subjects: 335
Study 12100328 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-P preparation
Number of subjects: 50
Study 12100328 — intervention group
Group type: COMPARATOR
Intervention: PEG preparation
Number of subjects: 50
Study 9842950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (titrated to a maximum of 200 mg/d for 12 weeks)
Number of subjects: 187
Study 9842950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 9842950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 187
Study 8128938 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bolus of p‐aminohippurate (PAH) 10 mg/kg
Number of subjects: 8
Study 8128938 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bolus of phenolsulfonphthalein (PSP) 1 mg/kg
Number of subjects: 8
Study 8128938 — intervention group
Group type: COMPARATOR
Intervention: Standard constant‐rate IV infusion of PAH
Number of subjects: 8
Study 2918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy with Gi-rep (MW 106,000)
Number of subjects: 0
Study 2918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy with Ei-M (MW 22,800)
Number of subjects: 0
Study 2918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy with DIIIa (MW 9980)
Number of subjects: 0
Study 2918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy (all antigens)
Number of subjects: 0
Study 2918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ei-M-specific IgG titer
Number of subjects: 0
Study 2918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ei-M-specific IgE titer
Number of subjects: 0
Study 2918184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy
Number of subjects: 0
Study 2918184 — intervention group
Group type: EXPERIMENTAL
Intervention: DIIIa
Number of subjects: 0
Study 791105 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol (M), 1 g/kg
Number of subjects: 11
Study 791105 — intervention group
Group type: COMPARATOR
Intervention: amphotericin B, 1 mg/kg
Number of subjects: 11
Study 11557169 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine augmentation
Number of subjects: 0
Study 11557169 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine antagonism of physostigmine's action
Number of subjects: 0
Study 11557169 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 0
Study 31055010 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot/carrot bar (B/C), n=45
Number of subjects: 256
Study 31055010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumpkin/sweet potato bar (P/S), n=44
Number of subjects: 256
Study 31055010 — intervention group
Group type: EXPERIMENTAL
Intervention: Boredom Group (beetroot/carrot bar at high frequency), n=47
Number of subjects: 256
Study 31055010 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral bar (no vegetables), n=46
Number of subjects: 256
Study 31055010 — intervention group
Group type: COMPARATOR
Intervention: Control Group, n=40
Number of subjects: 256
Study 29855372 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha Brain nootropic supplement (1925 mg, 3 pills per day: 2 pills at breakfast, 1 pill at dinner)
Number of subjects: 43
Study 29855372 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha Brain nootropic supplement
Number of subjects: 43
Study 29855372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 27694266 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC early (started ≤7 days after event)
Number of subjects: 204
Study 27694266 — intervention group
Group type: COMPARATOR
Intervention: DOAC late (started >7 days after event)
Number of subjects: 204
Study 27694266 — intervention group
Group type: COMPARATOR
Intervention: VKA (Vitamin K Antagonists)
Number of subjects: 204
Study 24529654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive use during the first 15 days
Number of subjects: 30
Study 24529654 — intervention group
Group type: COMPARATOR
Intervention: No use of adhesive during the first 15 days
Number of subjects: 30
Study 24529654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive use influenced the area covered with biofilm on the internal surfaces of the complete dentures
Number of subjects: 30
Study 22035647 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative counseling (Treatment group)
Number of subjects: 141
Study 22035647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative counseling)
Number of subjects: 141
Study 22035647 — intervention group
Group type: COMPARATOR
Intervention: Reference group (consented but did not participate in counseling)
Number of subjects: 141
Study 20136176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant (CI) listeners
Number of subjects: 2
Study 20136176 — intervention group
Group type: COMPARATOR
Intervention: Normally hearing (NH) listeners
Number of subjects: 2
Study 17374708 — intervention group
Group type: COMPARATOR
Intervention: iv bolus endotoxin [lipopolysaccharide (LPS), 3 ng/kg]
Number of subjects: 20
Study 16351674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (2 cc of 10 mg)
Number of subjects: 100
Study 16351674 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 cc)
Number of subjects: 100
Study 12851665 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Pharmaceutical Care (EC)
Number of subjects: 631
Study 10349117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diphenhydramine (DPH)
Number of subjects: 7
Study 10349117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diphenhydramine (DPH)
Number of subjects: 7
Study 10349117 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional score after oral DPH
Number of subjects: 7
Study 7502136 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-fat graft
Number of subjects: 156
Study 7502136 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam
Number of subjects: 156
Study 7502136 — intervention group
Group type: EXPERIMENTAL
Intervention: No interposition membrane
Number of subjects: 156
Study 2019162 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol, 90 micrograms by inhalation four times a day
Number of subjects: 27
Study 2019162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2019162 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 27
Study 7460650 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (13 patients)
Number of subjects: 28
Study 7460650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 patients)
Number of subjects: 28
Study 31488225 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller than normal portion size
Number of subjects: 82
Study 31488225 — intervention group
Group type: COMPARATOR
Intervention: Small-normal portion size
Number of subjects: 82
Study 31488225 — intervention group
Group type: COMPARATOR
Intervention: Large-normal portion size
Number of subjects: 82
Study 31337518 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative peer education
Number of subjects: 70
Study 31337518 — intervention group
Group type: COMPARATOR
Intervention: Routine education by a nurse
Number of subjects: 70
Study 30280751 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated garlic
Number of subjects: 41
Study 30280751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato extract
Number of subjects: 41
Study 30280751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of microencapsulated garlic and tomato extract
Number of subjects: 41
Study 30280751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 27120177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 104
Study 27120177 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 3435C>T alleles
Number of subjects: 104
Study 25057199 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous perceptual experience with the ambiguous visual stimulus
Number of subjects: 0
Study 25057199 — intervention group
Group type: COMPARATOR
Intervention: Previous stimulus presentations regardless of perception
Number of subjects: 0
Study 21707811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/day
Number of subjects: 86
Study 21707811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 19224365 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatment (EBT) for child PTSD
Number of subjects: 0
Study 19224365 — intervention group
Group type: EXPERIMENTAL
Intervention: School screening in schools in New Orleans
Number of subjects: 0
Study 17462100 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 978
Study 17462100 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 978
Study 17462100 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary utility measures
Number of subjects: 978
Study 17462100 — intervention group
Group type: EXPERIMENTAL
Intervention: All utility measures
Number of subjects: 978
Study 15225188 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) induced labor
Number of subjects: 88
Study 15225188 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(2) induced labor
Number of subjects: 88
Study 15225188 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous active labor
Number of subjects: 88
Study 12063523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal glucocorticoid (fluticasone propionate aqueous nasal spray [FPANS], 200 microg/d)
Number of subjects: 62
Study 12063523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of montelukast (10 mg/d) and antihistamine (loratadine, 10 mg/d)
Number of subjects: 62
Study 12063523 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d)
Number of subjects: 62
Study 12063523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9802705 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable controlled-release delivery system containing doxycycline hyclate (8.5% w/w)
Number of subjects: 32
Study 9802705 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline (200 mg on day 0, then 100 mg/day for 7 days)
Number of subjects: 32
Study 7702024 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 14
Study 7702024 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 14
Study 7702024 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT) and Medium-chain triglycerides (MCT)
Number of subjects: 14
Study 7702024 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 14
Study 2503294 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC)
Number of subjects: 704
Study 2503294 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine device (IUD)
Number of subjects: 704
Study 404157 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) 50 U i.v. followed by 2 U/min infusion for 60-90 min
Number of subjects: 6
Study 404157 — intervention group
Group type: COMPARATOR
Intervention: Control (no PTH)
Number of subjects: 6
Study 31429876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) for 30 minutes
Number of subjects: 1018
Study 31429876 — intervention group
Group type: COMPARATOR
Intervention: T-piece ventilation for 2 hours
Number of subjects: 1018
Study 26659730 — intervention group
Group type: EXPERIMENTAL
Intervention: LF rTMS (1 Hz)
Number of subjects: 20
Study 26659730 — intervention group
Group type: EXPERIMENTAL
Intervention: HF rTMS (10 Hz)
Number of subjects: 20
Study 26659730 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 26360645 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate video feedback (IVF) training
Number of subjects: 18
Study 26360645 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (control)
Number of subjects: 18
Study 23552023 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS drinking assessments with feedback (SA+F) for 12 weeks
Number of subjects: 0
Study 23552023 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS drinking assessments without feedback (SA) for 12 weeks
Number of subjects: 0
Study 23552023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 23552023 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 21342490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5699
Study 21342490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5699
Study 21342490 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 5699
Study 21342490 — intervention group
Group type: EXPERIMENTAL
Intervention: Country (Scotland vs Netherlands)
Number of subjects: 5699
Study 21342490 — intervention group
Group type: EXPERIMENTAL
Intervention: Country (Ireland vs Netherlands)
Number of subjects: 5699
Study 21342490 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure
Number of subjects: 5699
Study 21342490 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE Score
Number of subjects: 5699
Study 21342490 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Factor VIII levels
Number of subjects: 5699
Study 19724276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus axitinib (Gem+A)
Number of subjects: 95
Study 19724276 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 95
Study 19724276 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dBP>90 mmHg
Number of subjects: 95
Study 17692922 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (150 mg single dose)
Number of subjects: 40
Study 17692922 — intervention group
Group type: EXPERIMENTAL
Intervention: Boric acid suppositories (600 mg daily for 14 days)
Number of subjects: 40
Study 15155324 — intervention group
Group type: EXPERIMENTAL
Intervention: IV parecoxib 40 mg followed by oral valdecoxib 40 mg
Number of subjects: 263
Study 15155324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 11678385 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% tilt experimental waveform (336 microF capacitor)
Number of subjects: 54
Study 11678385 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% tilt experimental waveform (336 microF capacitor)
Number of subjects: 54
Study 11678385 — intervention group
Group type: COMPARATOR
Intervention: Standard 140 microF 80% tilt biphasic waveform (two 280 microF capacitors in series)
Number of subjects: 54
Study 9862047 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoendocrine therapy (mitozantrone and methotrexate (+/‐ mitomycin‐C) combined with tamoxifen)
Number of subjects: 309
Study 9862047 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy
Number of subjects: 309
Study 9862047 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoendocrine therapy
Number of subjects: 309
Study 9862047 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant and adjuvant therapy
Number of subjects: 309
Study 7832334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg orally)
Number of subjects: 12
Study 7832334 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg/70 kg intravenously)
Number of subjects: 12
Study 7832334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 micrograms/70 kg intravenously)
Number of subjects: 12
Study 7832334 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (70 mg/70 kg intravenously)
Number of subjects: 12
Study 7832334 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally and intravenously)
Number of subjects: 12
Study 2114989 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study 2114989 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (600 micrograms)
Number of subjects: 7